Total raised
—
Last: Undisclosed
Stage
Acquired
Founded
1999
Headcount
31
HQ
Modi'in-Maccabim-Re'ut
Sector
Health Tech & Life Sciences
About
Glycominds International, an innovative diagnostics company, develops and commercializes gastrointestinal disease management tools and services. Glycominds' GI dry serum testing allow physicians to help identify patients who have Celiac Disease and Inflammatory Bowel Diseases (mainly Crohns Disease and Ulcerative Colitis) to achieve early, non-invasive, accurate and cost-effective diagnosis, predict Crohns Disease patients at a higher risk for more complicated disease, as well as monitoring Anti-TNF therapy. Glycominds was acquired by Medivie Therapeutic in 2014, expanding its product line.
Funding history · 1 round · — total
Date unknown
Undisclosed
Undisclosed
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is Glycominds' primary focus in molecular diagnostics?
- Glycominds specializes in developing and commercializing gastrointestinal disease management tools and services, particularly focusing on Celiac Disease and Inflammatory Bowel Diseases like Crohn's Disease and Ulcerative Colitis.
- When was Glycominds founded?
- Glycominds was founded in January 1999.
- Where is Glycominds' headquarters located?
- Glycominds' headquarters is located in Modi'in-Maccabim-Re'ut, Center District, Israel.
- When was Glycominds acquired and by which company?
- Glycominds was acquired by Medivie Therapeutic in April 2014.
- What was a significant financial event for Glycominds in February 2011?
- In February 2011, Glycominds successfully completed an IPO on the TASE (Tel Aviv Stock Exchange).
- How many employees did Glycominds have?
- Glycominds had 31 employees.
- Who are the founders of Glycominds?
- The founders of Glycominds are Nir Dotan and Avi (Avinoam) Dukler, Ph.D.
- Which investor participated in an undisclosed funding round for Glycominds?
- Coronis Partners participated in an undisclosed funding round for Glycominds.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesDigital HealthcareDigital Medical Diagnostics
Technologies
Materials & SubstancesNanomaterials
Target customers
Healthcare & Life SciencesHealthcareLaboratoriesMedical Devices IndustryMedical Equipment
Business model
B2B
Tags
chronic-deseasescrohn-s-diseasepharmaceuticalsceliac-diseaseautoimmune-diseases